Profile data is unavailable for this security.
About the company
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
- Revenue in USD (TTM)1.20m
- Net income in USD-28.32m
- Incorporated2021
- Employees105.00
- LocationRani Therapeutics Holdings Inc2051 Ringwood AvenueSAN JOSE 95131United StatesUSA
- Phone+1 (408) 457-3700
- Fax+1 (302) 655-5049
- Websitehttps://www.ranitherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProQR Therapeutics NV | 18.67m | -49.44m | 158.02m | 166.00 | -- | 2.44 | -- | 8.47 | -0.4754 | -0.4754 | 0.1797 | 0.6153 | 0.139 | -- | 9.70 | 112,450.70 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Fate Therapeutics Inc | 6.65m | -136.32m | 159.28m | 161.00 | -- | 0.7628 | -- | 23.97 | -1.15 | -1.15 | 0.056 | 1.80 | 0.0175 | -- | 2.58 | 41,279.50 | -35.89 | -32.10 | -39.80 | -36.05 | -- | -- | -2,051.08 | -414.22 | -- | -- | 0.00 | -- | -51.24 | -26.71 | 26.82 | -- | 3.83 | -- |
| Microbot Medical Inc | 0.00 | -13.07m | 160.51m | 21.00 | -- | 2.01 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| Jyong Biotech Ltd | 0.00 | -2.95m | 162.70m | 29.00 | -- | -- | -- | -- | -0.0397 | -0.0397 | 0.00 | -0.3027 | 0.00 | -- | -- | 0.00 | -13.35 | -- | -127.41 | -- | -- | -- | -- | -- | -- | -1.96 | 2.79 | -- | -- | -- | 31.39 | -- | -- | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 164.50m | 147.00 | -- | 1.16 | -- | 17.70 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 165.34m | 131.00 | -- | 2.54 | -- | 15.75 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| MDxHealth SA | 103.07m | -31.43m | 165.82m | 312.00 | -- | -- | -- | 1.61 | -0.7275 | -0.7275 | 2.21 | -0.1669 | 0.6614 | 7.00 | 6.20 | 330,349.30 | -20.17 | -40.27 | -29.24 | -50.75 | 64.48 | 57.38 | -30.50 | -76.84 | 1.02 | -0.8112 | 1.10 | -- | 28.29 | 50.19 | 11.67 | -- | 96.87 | -- |
| Rani Therapeutics Holdings Inc | 1.20m | -28.32m | 167.70m | 105.00 | -- | -- | -- | 139.75 | -0.7906 | -0.7906 | 0.0322 | -0.1093 | 0.0447 | -- | -- | 11,428.57 | -177.34 | -64.50 | -603.19 | -106.31 | -- | -- | -3,966.50 | -6,123.18 | -- | -14.32 | 8.66 | -- | -- | 0.9816 | 11.63 | -- | -29.88 | -- |
| Zentalis Pharmaceuticals Inc | 26.87m | -149.32m | 171.96m | 166.00 | -- | 0.68 | -- | 6.40 | -2.08 | -2.08 | 0.3743 | 3.50 | 0.0691 | -- | -- | 161,837.30 | -38.39 | -43.59 | -43.54 | -49.56 | -- | -- | -555.80 | -1,402.74 | -- | -- | 0.00 | -- | -- | -- | 43.24 | -- | -8.89 | -- |
| Canton Strategic Holdings Inc | 0.00 | -10.32m | 174.31m | 2.00 | -- | 5.41 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 176.18m | 6.00 | -- | 4.21 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 180.05m | 105.00 | -- | 6.42 | -- | 1.21 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Insight Molecular Diagnostics Inc | 4.40m | -60.78m | 180.68m | 46.00 | -- | -- | -- | 41.04 | -2.83 | -2.83 | 0.1643 | -0.3213 | 0.0771 | 5.67 | 18.85 | 95,695.65 | -106.49 | -41.57 | -124.80 | -46.86 | 54.73 | 24.70 | -1,380.69 | -2,290.77 | 2.73 | -171.82 | -- | -- | 25.15 | -- | -136.17 | -- | -10.88 | -- |
| Nkarta Inc | 0.00 | -102.61m | 182.55m | 105.00 | -- | 0.5402 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 182.77m | 14.00 | -- | 1.53 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 183.80m | 8.00 | -- | 18.86 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
Data as of Mar 03 2026. Currency figures normalised to Rani Therapeutics Holdings Inc's reporting currency: US Dollar USD
25.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2025 | 8.50m | 8.71% |
| AWM Investment Co., Inc.as of 31 Dec 2025 | 6.50m | 6.66% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.62m | 4.74% |
| Longaeva Partners LPas of 31 Dec 2025 | 2.11m | 2.17% |
| Geode Capital Management LLCas of 31 Dec 2025 | 860.94k | 0.88% |
| 683 Capital Management LLCas of 31 Dec 2025 | 487.17k | 0.50% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 455.05k | 0.47% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 449.13k | 0.46% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 387.04k | 0.40% |
| Squarepoint OPS LLCas of 31 Dec 2025 | 344.38k | 0.35% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
